<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02055079</url>
  </required_header>
  <id_info>
    <org_study_id>V5.1/20.1.2013</org_study_id>
    <secondary_id>2012-000550-60</secondary_id>
    <secondary_id>15170</secondary_id>
    <secondary_id>1060/2012</secondary_id>
    <nct_id>NCT02055079</nct_id>
  </id_info>
  <brief_title>Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease</brief_title>
  <acronym>RAP</acronym>
  <official_title>Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sirolimus (SIR) has lead to a reduction of overall kidney size, a decrease in cyst density
      and general tubular cell proliferation in animal models, and to a reduction of the increase
      in creatinine and blood urea nitrogen by 34 and 39 percent respectively, as well as a
      reduction of cyst proliferation, expressed by a 30 percent reduction of overall kidney
      enlargement, a reduction in general cyst volume, and a reduction of the cyst volume density
      in the renal cortex in humans.

      However, despite promising data from animal- and in vivo studies, most mammalian target of
      rapamycin inhibitor (mTOR-I) studies in patients with autosomal-dominant polycystic kidney
      disease (ADPKD) produced only subtle if any clinically relevant effects on cyst growth and
      the preservation of renal function.

      In this study we will investigate if pulsed administration of SIR in a fixed weekly oral dose
      of 3 mg over 24 months compared to placebo significantly reduces cyst growth and preserves
      excretory renal function in patients with ADPKD and an estimated glomerular filtration (eGFR)
      rate below 60 mL/min per 1.73m2.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in kidney function from baseline to month 24</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Fifty percent reduction in doubling of serum creatinine, or initiation of dialysis over a period of two years. Less or equal than 1.5 fold increase in serum creatinine without initiation of dialysis over two years is considered a beneficial outcome, increases in serum creatinine greater than 1.5 over two years or initiation of dialysis are considered a non-beneficial outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of safety parameters from baseline to month 24</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Safety, change in proteinuria, as indicated by albumin/creatinine- and protein/creatinine ratio, respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Polycystic Kidney, Type 1 Autosomal Dominant Disease</condition>
  <condition>Polycystic Kidney, Type 2 Autosomal Dominant Disease</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed oral dose of 3 mg Sirolimus (blinded) once weekly for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fixed oral dose of placebo (blinded) once weekly for 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Fixed oral dose of 3 mg sirolimus (blinded) once weekly for 24 months.</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Fixed oral dose of 3 mg placebo (blinded) once weekly for 24 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ADPKD, as confirmed by history, ultrasound, computed- or magnetic resonance tomography

          -  Eighteen years of age, or older

          -  Baseline eGFR below 60 mL/min per 1.73m2

          -  Negative serum pregnancy test prior to administration of sirolimus and agreement to
             use contraception throughout the study and three months after

          -  Written informed consent

        Exclusion Criteria:

          -  Need for renal replacement therapy

          -  Pregnancy/lactation

          -  Plans to become pregnant in the near future

          -  Refusal to use sufficient contraception

          -  Proteinuria as defined as protein:creatinine ratio &gt;1000 or &gt;1g/d, respectively

          -  History of life threatening complications of ADPKD

          -  Evidence of active systemic- or localized major infection

          -  Evidence of infiltrate or consolidation on chest X-ray

          -  Use of any investigational drug or -treatment up to 4 weeks prior to enrolment and
             during the study

          -  Known allergy/hypersensitivity to sirolimus and its derivatives

          -  Medication that will interfere with the cytochrome P450 (CYP3A4/CYP3A5) system

          -  Total white blood cell count below or equal to 3000/mm3

          -  Platelet count below or equal to 100.000/mm3

          -  Fasting triglycerides above or equal to 400 mg/dL

          -  Fasting total cholesterol above or equal to 300 mg/dL

          -  Concomitant glomerular diseases

          -  Psychiatric disorders and any condition that might prevent full comprehension of the
             purposes and risks of the study

          -  History of malignancy, with the exception of adequately treated basal cell- and
             squamous cell carcinoma of the skin

          -  HIV positivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Riegersperger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gere Sunder-Plassmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Riegersperger, MD</last_name>
    <phone>0043140400</phone>
    <phone_ext>4391</phone_ext>
    <email>markus.riegersperger@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gere Sunder-Plassmann, MD</last_name>
    <phone>0043140400</phone>
    <phone_ext>4391</phone_ext>
    <email>gere.sunder-plassmann@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Riegersperger, MD</last_name>
      <phone>0043140400</phone>
      <phone_ext>4391</phone_ext>
      <email>markus.riegersperger@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Gere Sunder-Plassmann, MD</last_name>
      <phone>0043140400</phone>
      <phone_ext>4391</phone_ext>
      <email>gere.sunder-plassmann@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Riegersperger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gere Sunder-Plassmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Markus Riegersperger, MD</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>ADPKD</keyword>
  <keyword>PKD</keyword>
  <keyword>Polycystic kidney disease</keyword>
  <keyword>Mammalian target of rapamycin</keyword>
  <keyword>mTOR-I</keyword>
  <keyword>Sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

